Check Point Software Technologies Ltd
Change company Symbol lookup
Select an option...
CHKP Check Point Software Technologies Ltd
CTXS Citrix Systems Inc
RAKR Rainmaker Worldwide Inc
CLB Core Laboratories NV
KERN Akerna Corp
T AT&T Inc
YPPN Yappn Corp
RUSHB Rush Enterprises Inc
CMTL Comtech Telecommunications Corp
BMYMP Bristol-Myers Squibb Co
Go

Information Technology : Software | Large Cap Blend
Based in Israel
Company profile

Check Point Software Technologies Ltd. (Check point) develops, markets and supports a range of products and services for information technology (IT) security. The Company's products and services are sold to enterprises, service providers, small and medium sized businesses and consumers. It offers enterprises a platform to deploy independent, modular and interoperable security applications (Software Blades), such as firewall, virtual private network (VPN), intrusion prevention system (IPS), Application Control, Anti-Bot, antivirus, data loss prevention (DLP), policy management, event analysis or multi-domain management. The Company offers Software Blades grouped into functional packages to address specific security issues. It has product offerings under these packages, which include Next Generation Firewall, Next Generation Threat Prevention, Next Generation Secure Web Gateway and Next Generation Data Protection.

Premarket

Last Trade
Delayed
$124.40
-0.06 (-0.05%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$124.46
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
5,818

10-day average volume:
827,854
5,818

DiscGenics Appoints Former Medtronic Spine and Biologics Finance Executive as First Chief Financial Officer

8:00 am ET September 9, 2020 (PR Newswire) Print

DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has appointed former Medtronic Spine and Biologics finance executive, Jeff Poole, as its first Chief Financial Officer (CFO).

https://mma.prnewswire.com/media/1250475/Jeff_Poole.jpg

Mr. Poole has over 13 years of progressive finance leadership experience in medical devices, and significant experience within the spine market, most recently serving as Vice President of Finance for Medtronic Spine and Biologics, a major division of Medtronic, PLC. In this role, he served as CFO for the global business unit with over $2.5 billion in annual revenue responsibility. Mr. Poole also has extensive international experience, particularly in Asia Pacific, where he held various leadership positions with increasing levels of functional and strategic responsibilities and commercial exposure to developed and emerging markets. He is also fluent in Japanese and has lived and worked extensively in Japan, where DiscGenics has a significant financial and commercial interest.

Mr. Poole's appointment closely follows DiscGenics's announcement last month that it raised $50 million in its Series C round of funding, bringing total investment in the Company to just over $71 million to-date.

"The addition of Jeff to the DiscGenics executive team represents a huge opportunity for us as we move through our final clinical stages and evaluate various financing and commercial opportunities going forward in the U.S. and Japan," said Flagg Flanagan, Chief Executive Officer and Chairman of the Board of Directors for DiscGenics.

Mr. Poole added, "I am thrilled to be joining DiscGenics because I truly believe its innovative regenerative therapy addresses an unmet clinical need and could significantly alter the definition of Standard of Care for patients suffering from spinal disc degeneration. I look forward to working with Flagg and the entire DiscGenics team to help realize the full clinical and commercial potential of IDCT for the millions of patients suffering from chronic low back pain worldwide."

As CFO, Mr. Poole will report directly to Mr. Flanagan.

About DiscGenicsDiscGenics is a privately held, clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics believes it has a unique opportunity to harness the restorative potential of the human body to heal millions of patients suffering from the debilitating effects of back pain. DiscGenics' first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy that utilizes biomedically engineered progenitor cells derived from intervertebral disc tissue, known as Discogenic Cells, to offer a non-surgical, potentially regenerative solution for the treatment of patients with mild to moderate degenerative disc disease. For more information, visit discgenics.com.

https://mma.prnewswire.com/media/561675/DiscGenics_Logo.jpg

https://c212.net/c/img/favicon.png?sn=LA18625&sd=2020-09-09

View original content to download multimedia:http://www.prnewswire.com/news-releases/discgenics-appoints-former-medtronic-spine-and-biologics-finance-executive-as-first-chief-financial-officer-301126111.html

SOURCE DiscGenics, Inc.

https://rt.prnewswire.com/rt.gif?NewsItemId=LA18625&Transmission_Id=202009090800PR_NEWS_USPR_____LA18625&DateId=20200909

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.